[en] Impaired glucose metabolism, decreased levels of thiamine and its phosphate esters, and reduced activity of thiamine-dependent enzymes, such as pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and transketolase occur in Alzheimer’s disease (AD). Thiamine deficiency exacerbates amyloid beta (Aβ) deposition, tau hyperphosphorylation, and oxidative stress. Benfotiamine (BFT) rescued cognitive deficits and reduced Aβ burden in APP/PS1 mice. In this study, we examined whether BFT confers neuroprotection against tau phosphorylation and the generation of neurofibrillary tangles (NFTs) in the P301S mouse model of tauopathy. Chronic dietary treatment with BFT increased lifespan, improved behavior, reduced glycated tau, decreased NFTs, and prevented death of motor neurons. BFT administration significantly ameliorated mitochondrial dysfunction and attenuated oxidative damage and inflammation. We found that BFT and its metabolites (but not thiamine) trigger the expression of Nrf2/ARE- dependent genes in mouse brain as well as in wild-type but not Nrf2-deficient fibroblasts. Active metabolites were more potent in activating the Nrf2 target genes than the parent molecule BFT. Docking studies showed that BFT and its metabolites (but not thiamine) bind to Keap1 with high affinity. These findings demonstrate that BFT activates the Nrf2/ARE pathway and is a promising therapeutic agent for the treatment of diseases with tau pathology, such as AD, frontotemporal dementia, and progressive supranuclear palsy.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Tapias, Victor
Jainuddin, Shari
Ahuja, Manuj
Stack, Cliona
Elipenahli, Ceyhan
Vignisse, Julie; Université de Liège > Département des maladies infectieuses et parasitaires (DMI) > Mycologie vétérinaire
Gerges, Meri
Starkova, Natalia
Xu, Hui
Starkov, Anatoly A.
Bettendorff, Lucien ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie et physiologie humaine et pathologique
Bettendorff, L. and Wins, P. (2009) Thiamin diphosphate in biological chemistry: new aspects of thiamin metabolism, especially triphosphate derivatives acting other than as cofactors. FEBS J., 276, 2917-2925.
Bettendorff, L. (1995) Thiamine homeostasis in neuroblastoma cells. Neurochem. Int., 26, 295-302.
Bettendorff, L., Mastrogiacomo, F., Kish, S.J. and Grisar, T. (2002) Thiamine, thiamine phosphates, and their metabolizing enzymes in human brain. J. Neurochem., 66, 250-258.
Gangolf, M., Czerniecki, J., Radermecker, M., Detry, O., Nisolle, M., Jouan, C., Martin, D., Chantraine, F., Lakaye, B. and Wins, P. (2010) Thiamine status in humans and content of phosphorylated thiamine derivatives in biopsies and cultured cells. PLoS One, 5, e13616.
Gibson, G.E., Sheu, K.F., Blass, J.P., Baker, A., Carlson, K.C., Harding, B. and Perrino, P. (1988) Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch. Neurol., 45, 836-840.
Ke, Z.J. and Gibson, G.E. (2004) Selective response of various brain cell types during neurodegeneration induced by mild impairment of oxidative metabolism. Neurochem. Int., 45, 361-369.
Gold, M., Chen, M.F. and Johnson, K. (1995) Plasma and red blood cell thiamine deficiency in patients with dementia of the Alzheimer's type. Arch. Neurol., 52, 1081-1086.
Gold, M., Hauser, R.A. and Chen, M.F. (1998) Plasma thiamine deficiency associated with Alzheimer's disease but not Parkinson's disease. Metab. Brain Dis., 13, 43-53.
Molina, J.A., Jimenez-Jimenez, F.J., Hernanz, A., Fernandez- Vivancos, E., Medina, S., de Bustos, F., Gomez-Escalonilla, C. and Sayed, Y. (2002) Cerebrospinal fluid levels of thiamine in patients with Alzheimer's disease. J. Neural Transm. (Vienna), 109, 1035-1044.
Heroux, M., Raghavendra Rao, V.L., Lavoie, J., Richardson, J.S. and Butterworth, R.F. (1996) Alterations of thiamine phosphorylation and of thiamine-dependent enzymes in Alzheimer's disease. Metab. Brain Dis., 11, 81-88.
Mastrogiacoma, F., Bettendorff, L., Grisar, T. and Kish, S.J. (1996) Brain thiamine, its phosphate esters, and its metabolizing enzymes in Alzheimer's disease. Ann. Neurol., 39, 585-591.
Rao, V.L., Richardson, J.S. and Butterworth, R.F. (1993) Decreased activities of thiamine diphosphatase in frontal and temporal cortex in Alzheimer's disease. Brain Res., 631, 334-336.
Bubber, P., Haroutunian, V., Fisch, G., Blass, J.P. and Gibson, G.E. (2005) Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann. Neurol., 57, 695-703.
Karuppagounder, S.S., Xu, H., Shi, Q., Chen, L.H., Pedrini, S., Pechman, D., Baker, H., Beal, M.F., Gandy, S.E. and Gibson, G.E. (2009) Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in Alzheimer's mouse model. Neurobiol. Aging, 30, 1587-1600.
Blass, J.P., Gleason, P., Brush, D., DiPonte, P. and Thaler, H. (1988) Thiamine and Alzheimer's disease. A pilot study. Arch. Neurol., 45, 833-835.
Meador, K., Loring, D., Nichols, M., Zamrini, E., Rivner, M., Posas, H., Thompson, E. and Moore, E. (1993) Preliminary findings of high-dose thiamine in dementia of Alzheimer's type. J. Geriatr. Psychiatry Neurol., 6, 222-229.
Nolan, K.A., Black, R.S., Sheu, K.F., Langberg, J. and Blass, J.P. (1991) A trial of thiamine in Alzheimer's disease. Arch. Neurol., 48, 81-83.
Calingasan, N.Y., Uchida, K. and Gibson, G.E. (1999) Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. J. Neurochem., 72, 751-756.
Lin, M.T. and Beal, M.F. (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 443, 787-795.
Mouton-Liger, F., Rebillat, A.S., Gourmaud, S., Paquet, C., Leguen, A., Dumurgier, J., Bernadelli, P., Taupin, V., Pradier, L. and Rooney, T. (2015) PKR downregulation prevents neurodegeneration and beta-amyloid production in a thiamine-deficient model. Cell Death Dis., 6, e1594.
Calingasan, N.Y., Park, L.C., Calo, L.L., Trifiletti, R.R., Gandy, S.E. and Gibson, G.E. (1998) Induction of nitric oxide synthase and microglial responses precede selective cell death induced by chronic impairment of oxidative metabolism. Am. J. Pathol., 153, 599-610.
Hazell, A.S., Faim, S., Wertheimer, G., Silva, V.R. and Marques, C.S. (2013) The impact of oxidative stress in thiamine deficiency: a multifactorial targeting issue. Neurochem. Int., 62, 796-802.
Volvert, M.L., Seyen, S., Piette, M., Evrard, B., Gangolf, M., Plumier, J.C. and Bettendorff, L. (2008) Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol., 8, 10.
Hammes, H.P., Du, X., Edelstein, D., Taguchi, T., Matsumura, T., Ju, Q., Lin, J., Bierhaus, A., Nawroth, P. and Hannak, D. (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med., 9, 294-299.
Balakumar, P., Rohilla, A., Krishan, P., Solairaj, P. and Thangathirupathi, A. (2010) The multifaceted therapeutic potential of benfotiamine. Pharmacol. Res., 61, 482-488.
Pan, X., Gong, N., Zhao, J., Yu, Z., Gu, F., Chen, J., Sun, X., Zhao, L., Yu, M. and Xu, Z. (2010) Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain, 133, 1342-1351.
Borchelt, D.R., Ratovitski, T., van Lare, J., Lee, M.K., Gonzales, V., Jenkins, N.A., Copeland, N.G., Price, D.L. and Sisodia, S.S. (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron, 19, 939-945.
Kurt, M.A., Davies, D.C., Kidd, M., Duff, K., Rolph, S.C., Jennings, K.H. and Howlett, D.R. (2001) Neurodegenerative changes associated with beta-amyloid deposition in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Exp. Neurol., 171, 59-71.
Arriagada, P.V., Growdon, J.H., Hedley-Whyte, E.T. and Hyman, B.T. (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology, 42, 631-639.
Spires-Jones, T.L., Stoothoff, W.H., de Calignon, A., Jones, P.B. and Hyman, B.T. (2009) Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci., 32, 150-159.
Dumont, M., Stack, C., Elipenahli, C., Jainuddin, S., Gerges, M., Starkova, N.N., Yang, L., Starkov, A.A. and Beal, F. (2011) Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice. FASEB J., 25, 4063-4072.
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.M., Iwata, N., Saido, T.C., Maeda, J., Suhara, T., Trojanowski, J.Q. and Lee, V.M. (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron, 53, 337-351.
Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Paul Murphy, M., Baker, M., Yu, X. et al. (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet., 25, 402-405.
Zhao, J., Sun, X., Yu, Z., Pan, X., Gu, F., Chen, J., Dong, W., Zhao, L. and Zhong, C. (2011) Exposure to pyrithiamine increases beta-amyloid accumulation, Tau hyperphosphorylation, and glycogen synthase kinase-3 activity in the brain. Neurotox. Res., 19, 575-583.
Tapias, V., Cannon, J.R. and Greenamyre, J.T. (2014) Pomegranate juice exacerbates oxidative stress and nigrostriatal degeneration in Parkinson's disease. Neurobiol. Aging, 35, 1162-1176.
Tapias, V., Hu, X., Luk, K.C., Sanders, L.H., Lee, V.M. and Greenamyre, J.T. (2017) Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production. Cell. Mol. Life Sci., 74, 2851-2874.
Castellani, R., Smith, M.A., Richey, P.L., Kalaria, R., Gambetti, P. and Perry, G. (1995) Evidence for oxidative stress in Pick disease and corticobasal degeneration. Brain Res., 696, 268-271.
Kaidery, N.A., Banerjee, R., Yang, L., Smirnova, N.A., Hushpulian, D.M., Liby, K.T., Williams, C.R., Yamamoto, M., Kensler, T.W., Ratan, R.R. et al. (2013) Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. Antioxid Redox Signal, 18, 139-157.
Stack, C., Ho, D., Wille, E., Calingasan, N.Y., Williams, C., Liby, K., Sporn, M., Dumont, M. and Beal, M.F. (2010) Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic. Biol. Med., 49, 147-158.
Hurt, J.K., Coleman, J.L., Fitzpatrick, B.J., Taylor-Blake, B., Bridges, A.S., Vihko, P. and Zylka, M.J. (2012) Prostatic acid phosphatase is required for the antinociceptive effects of thiamine and benfotiamine. PLoS One, 7, e48562.
Smirnova, N.A., Haskew-Layton, R.E., Basso, M., Hushpulian, D.M., Payappilly, J.B., Speer, R.E., Ahn, Y.H., Rakhman, I., Cole, P.A., Pinto, J.T. et al. (2011) Development of Neh2-luciferase reporter and its application for high throughput screening and real-time monitoring of Nrf2 activators. Chem. Biol., 18, 752-765.
Steel, R., Cowan, J., Payerne, E., O'Connell, M.A. and Searcey, M. (2012) Anti-inflammatory effect of a cell-penetrating peptide targeting the Nrf2/Keap1 interaction. ACS Med. Chem. Lett., 3, 407-410.
Marcotte, D., Zeng, W., Hus, J.-C., McKenzie, A., Hession, C., Jin, P., Bergeron, C., Lugovskoy, A., Enyedy, I., Cuervo, H. et al. (2013) Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism. Bioorg. Med. Chem., 21, 4011-4019.
Vlassenko, A.G., Vaishnavi, S.N., Couture, L., Sacco, D., Shannon, B.J., Mach, R.H., Morris, J.C., Raichle, M.E. and Mintun, M.A. (2010) Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta) deposition. Proc. Natl. Acad. Sci. USA., 107, 17763-17767.
Bateman, R.J., Xiong, C., Benzinger, T.L., Fagan, A.M., Goate, A., Fox, N.C., Marcus, D.S., Cairns, N.J., Xie, X., Blazey, T.M. et al. (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med., 367, 795-804.
Takeuchi, H., Iba, M., Inoue, H., Higuchi, M., Takao, K., Tsukita, K., Karatsu, Y., Iwamoto, Y., Miyakawa, T., Suhara, T. et al. (2011) P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PLoS One, 6, e21050.
Vignisse, J., Sambon, M., Gorlova, A., Pavlov, D., Caron, N., Malgrange, B., Shevtsova, E., Svistunov, A., Anthony, D.C., Markova, N. et al. (2017) Thiamine and benfotiamine prevent stress-induced suppression of hippocampal neurogenesis in mice exposed to predation without affecting brain thiamine diphosphate levels. Mol. Cell Neurosci., 82, 126-136.
Rossouw, J.E., Labadarios, D., Krasner, N., Davis, M. and Williams, R. (1978) Red blood cell transketolase activity and the effect of thiamine supplementation in patients with chronic liver disease. Scand. J. Gastroenterol., 13, 133-138.
Xu, I.M., Lai, R.K., Lin, S.H., Tse, A.P., Chiu, D.K., Koh, H.Y., Law, C.T., Wong, C.M., Cai, Z., Wong, C.C. et al. (2016) Transketolase counteracts oxidative stress to drive cancer development. Proc. Natl. Acad. Sci. USA., 113, E725-E734.
Esposito, L., Raber, J., Kekonius, L., Yan, F., Yu, G.Q., Bien-Ly, N., Puolivali, J., Scearce-Levie, K., Masliah, E. and Mucke, L. (2006) Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice. J. Neurosci., 26, 5167-5179.
Melov, S., Adlard, P.A., Morten, K., Johnson, F., Golden, T.R., Hinerfeld, D., Schilling, B., Mavros, C., Masters, C.L., Volitakis, I. et al. (2007) Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS One, 2, e536.
Qin, W., Haroutunian, V., Katsel, P., Cardozo, C.P., Ho, L., Buxbaum, J.D. and Pasinetti, G.M. (2009) PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch. Neurol., 66, 352-361.
Cui, L., Jeong, H., Borovecki, F., Parkhurst, C.N., Tanese, N. and Krainc, D. (2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell, 127, 59-69.
Shin, J.H., Ko, H.S., Kang, H., Lee, Y., Lee, Y.I., Pletinkova, O., Troconso, J.C., Dawson, V.L. and Dawson, T.M. (2011) PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell, 144, 689-702.
Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A., Cinti, S., Lowell, B., Scarpulla, R.C. et al. (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell, 98, 115-124.
Coskun, P.E., Wyrembak, J., Derbereva, O., Melkonian, G., Doran, E., Lott, I.T., Head, E., Cotman, C.W. and Wallace, D.C. (2010) Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia. J. Alzheimers Dis., 20, S293-S310.
Manczak, M., Calkins, M.J. and Reddy, P.H. (2011) Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum. Mol. Genet., 20, 2495-2509.
DuBoff, B., Gotz, J. and Feany, M.B. (2012) Tau promotes neurodegeneration via DRP1 mislocalization in vivo. Neuron, 75, 618-632.
Wang, W., Yin, J., Ma, X., Zhao, F., Siedlak, S.L., Wang, Z., Torres, S., Fujioka, H., Xu, Y., Perry, G. and Zhu, X. (2017) Inhibition of mitochondrial fragmentation protects against Alzheimer's disease in rodent model. Hum. Mol. Genet, 26, 4118-4131.
Vicente Miranda, H., Szego, E.M., Oliveira, L.M., Breda, C., Darendelioglu, E., de Oliveira, R.M., Ferreira, D.G., Gomes, M.A., Rott, R., Oliveira, M. et al. (2017) Glycation potentiates alpha-synuclein-associated neurodegeneration in synucleinopathies. Brain, 140, 1399-1419.
Smith, M.A., Taneda, S., Richey, P.L., Miyata, S., Yan, S.D., Stern, D., Sayre, L.M., Monnier, V.M. and Perry, G. (1994) Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA., 91, 5710-5714.
Sasaki, N., Fukatsu, R., Tsuzuki, K., Hayashi, Y., Yoshida, T., Fujii, N., Koike, T., Wakayama, I., Yanagihara, R., Garruto, R. et al. (1998) Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am. J. Pathol., 153, 1149-1155.
Vitek, M.P., Bhattacharya, K., Glendening, J.M., Stopa, E., Vlassara, H., Bucala, R., Manogue, K. and Cerami, A. (1994) Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl.Acad. Sci. USA., 91, 4766-4770.
Castellani, R.J., Harris, P.L., Sayre, L.M., Fujii, J., Taniguchi, N., Vitek, M.P., Founds, H., Atwood, C.S., Perry, G. and Smith, M.A. (2001) Active glycation in neurofibrillary pathology of Alzheimer disease: n (epsilon)-(carboxymethyl) lysine and hexitol-lysine. Free Radic. Biol. Med., 31, 175-180.
Yan, S.D., Yan, S.F., Chen, X., Fu, J., Chen, M., Kuppusamy, P., Smith, M.A., Perry, G., Godman, G.C., Nawroth, P., Zweier, J.L. and Stern, D. (1995) Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat. Med., 1, 693-699.
Li, J., Liu, D., Sun, L., Lu, Y. and Zhang, Z. (2012) Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. J. Neurol. Sci., 317, 1-5.
Mecocci, P., MacGarvey, U. and Beal, M.F. (1994) Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol., 36, 747-751.
Albers, D.S., Augood, S.J., Martin, D.M., Standaert, D.G., Vonsattel, J.P. and Beal, M.F. (1999) Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy. J. Neurochem., 73, 881-884.
Park, L.C., Albers, D.S., Xu, H., Lindsay, J.G., Beal, M.F. and Gibson, G.E. (2001) Mitochondrial impairment in the cerebellum of the patients with progressive supranuclear palsy. J. Neurosci. Res., 66, 1028-1034.
Schmid, U., Stopper, H., Heidland, A. and Schupp, N. (2008) Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro. Diabetes Metab. Res. Rev., 24, 371-377.
Wu, S. and Ren, J. (2006) Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-alpha. Neurosci. Lett., 394, 158-162.
Mrak, R.E. and Griffin, W.S. (2005) Potential inflammatory biomarkers in Alzheimer's disease. J. Alzheimers Dis., 8, 369-375.
Pasinetti, G.M. and Aisen, P.S. (1998) Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience, 87, 319-324.
Vodovotz, Y., Lucia, M.S., Flanders, K.C., Chesler, L., Xie, Q.W., Smith, T.W., Weidner, J., Mumford, R., Webber, R. and Nathan, C. (1996) Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J. Exp. Med., 184, 1425-1433.
Nathan, C., Calingasan, N., Nezezon, J., Ding, A., Lucia, M.S., La Perle, K., Fuortes, M., Lin, M., Ehrt, S., Kwon, N.S. et al. (2005) Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J. Exp. Med., 202, 1163-1169.
Huang, K.L., Marcora, E., Pimenova, A.A., Di Narzo, A.F., Kapoor, M., Jin, S.C., Harari, O., Bertelsen, S., Fairfax, B.P., Czajkowski, J. et al. (2017) A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease. Nat. Neurosci., 20, 1052.
Huang, K.L., Marcora, E., Pimenova, A.A., Di Narzo, A.F., Kapoor, M., Jin, S.C., Harari, O., Bertelsen, S., Fairfax, B.P., Czajkowski, J. et al. (2017) A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease. Nat. Neurosci., 20, 1052.
Bellucci, A., Westwood, A.J., Ingram, E., Casamenti, F., Goedert, M. and Spillantini, M.G. (2004) Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am. J. Pathol., 165, 1643-1652.
Shoeb, M. and Ramana, K.V. (2012) Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages. Free Radic. Biol. Med., 52, 182-190.
Yadav, U.C., Kalariya, N.M., Srivastava, S.K. and Ramana, K.V. (2010) Protective role of benfotiamine, a fat-soluble vitamin B1 analogue, in lipopolysaccharide-induced cytotoxic signals in murine macrophages. Free Radic. Biol. Med., 48, 1423-1434.
Dinkova-Kostova, A.T. and Abramov, A.Y. (2015) The emerging role of Nrf2 in mitochondrial function. Free Radic. Biol. Med., 88, 179-188.
Xue, M., Rabbani, N., Momiji, H., Imbasi, P., Anwar, M.M., Kitteringham, N., Park, B.K., Souma, T., Moriguchi, T., Yamamoto, M. et al. (2012) Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. Biochem. J., 443, 213-222.
Ramsey, C.P., Glass, C.A., Montgomery, M.B., Lindl, K.A., Ritson, G.P., Chia, L.A., Hamilton, R.L., Chu, C.T. and Jordan- Sciutto, K.L. (2007) Expression of Nrf2 in neurodegenerative diseases. J. Neuropathol. Exp. Neurol., 66, 75-85.
Kanninen, K., Heikkinen, R., Malm, T., Rolova, T., Kuhmonen, S., Leinonen, H., Yla-Herttuala, S., Tanila, H., Levonen, A.L., Koistinaho, M. et al. (2009) Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA., 106, 16505-16510.
Joshi, G., Gan, K.A., Johnson, D.A. and Johnson, J.A. (2014) Increased Alzheimer's disease-like pathology in the APP/PS1DeltaE9 mouse model lacking Nrf2 through modulation of autophagy. Neurobiol. Aging, 36, 664-679.
Dumont, M., Wille, E., Calingasan, N.Y., Tampellini, D., Williams, C., Gouras, G.K., Liby, K., Sporn, M., Flint Beal, M., Lin, M.T. et al. (2009) Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease. J. Neurochem., 109, 502-512.
Lastres-Becker, I., Innamorato, N.G., Jaworski, T., Rabano, A., Kugler, S., Van Leuven, F. and Cuadrado, A. (2014) Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis. Brain, 137, 78-91.
Stack, C., Jainuddin, S., Elipenahli, C., Gerges, M., Starkova, N., Starkov, A.A., Jove, M., Portero-Otin, M., Launay, N., Pujol, A. et al. (2014) Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Hum. Mol. Genet., 23, 3716-3732.
Ahuja, M., Ammal Kaidery, N., Yang, L., Calingasan, N., Smirnova, N., Gaisin, A., Gaisina, I.N., Gazaryan, I., Hushpulian, D.M., Kaddour-Djebbar, I. et al. (2016) Distinct Nrf2 signaling mechanisms of fumaric acid esters and their role in neuroprotection against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine- induced experimental Parkinson's-like disease. J. Neurosci., 36, 6332-6351.
Kimura, R. and Ohno, M. (2009) Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol. Dis., 33, 229-235.
Shepherd, D. and Garland, P.B. (1969) The kinetic properties of citrate synthase from rat liver mitochondria. Biochem. J., 114, 597-610.
Veeger, C., Der Vartanian, D.V. and Zeylemaker, W.P. (1969) Succinate dehydrogenase. Methods Enzymol., 13, 81-90.
D'Aurelio, M., Vives-Bauza, C., Davidson, M.M. and Manfredi, G. (2010) Mitochondrial DNA background modifies the bioenergetics of NARP/MILS ATP6 mutant cells. Hum. Mol. Genet., 19, 374-386.